Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.22B | $187.00M | $0.72 |
| 2024 | $6.40B | $864.00M | $3.36 |
| 2023 | $6.26B | $1.02B | $4.01 |
| 2022 | $6.17B | $917.00M | $3.61 |
| 2021 | $6.30B | $1.35B | $5.33 |
Social Signal Score
Earnings
Mon, Nov 9(in 3 months)
Consensus estimate $0.91 per share
Typical surprise -2.2% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Jul 31$0.41 vs $0.91miss
- Thu, Apr 30$0.71 vs $0.83miss
- Thu, Feb 12$0.63 vs $0.73miss
- Mon, Nov 10$1.01 vs $0.93beat
- Tue, Aug 5$1.00 vs $0.94beat
- Thu, May 1$1.02 vs $0.89beat
Estimates and results for OGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from OGN's reported EPS growth of -39.4% a year over 4 years. Historical EPS growth of -39% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.32
- Implied price
- $3.20
- Return from $13.72
- -25.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.59 — -88.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 6 | 8 | 10 | 12 | 14 |
|---|---|---|---|---|---|
| -25.0% | -40.5% | -36.9% | -34.1% | -31.6% | -29.5% |
| -20.0% | -36.5% | -32.7% | -29.7% | -27.1% | -24.8% |
| -15.0% | -32.5% | -28.5% | -25.3% | -22.5% | -20.1% |
| -10.0% | -28.6% | -24.3% | -20.9% | -17.9% | -15.4% |
| -5.0% | -24.6% | -20.1% | -16.5% | -13.4% | -10.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsbusinesswire.com·4d ago·Neutral
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability JERSEY CITY, N.J.--(BUSINESS WIRE)--HCPs, healthcare settings and pharmacies can begin REMS certification for Organon's hormone-free copper IUD, MIUDELLA, ahead of upcoming launch.
View source ↗